• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Molecular Sciences >A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor
【24h】

A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor

机译：一种新型的LMP1抗体与丝裂霉素C协同通过诱导细胞凋亡和下调血管内皮生长因子来抑制鼻咽癌的体内生长。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Combined therapy emerges as an attractive strategy for cancer treatment. The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice. The inhibitory rates of MMC (2 mg/kg), Fab (4 mg/kg), MMC (2 mg/kg) + Fab (4 mg/kg), and MMC (1 mg/kg) + Fab (4 mg/kg) were 20.1%, 7.3%, 42.5% and 40.5%, respectively. Flow cytometry analysis showed that the apoptotic rate of xenograft tumor cells in the MMC and Fab combination group was 28 ± 4.12%, significantly higher than the MMC (2 mg/kg) group (P 0.01). Immunohistochemical staining showed that VEGF expression in NPC xenografts was significantly inhibited in the combination group compared to the Fab (4 mg/kg) group (P 0.05). In conclusion, both MMC and Fab could inhibit NPC xenograft tumor growth in vivo and combination therapy showed apparent synergistic anti-tumor effects, which may be due to the induction of tumor cell apoptosis and the downregulation of VEGF expression. These results suggest that the novel combined therapy utilizing traditional chemotherapeutics and antibody-targeted therapy could be a promising strategy for the treatment of NPC.
机译：联合治疗已成为一种有吸引力的癌症治疗策略。这项研究的目的是研究丝裂霉素C（MMC）与靶向潜伏膜蛋白1（LMP1）的新型抗体片段（Fab）联合对鼻咽癌（NPC）异种移植裸鼠的抑制作用。 MMC（2 mg / kg），Fab（4 mg / kg），MMC（2 mg / kg）+ Fab（4 mg / kg）和MMC（1 mg / kg）+ Fab（4 mg / kg）的抑制率公斤）分别为20.1％，7.3％，42.5％和40.5％。流式细胞仪分析表明，MMC与Fab联合治疗组的异种移植肿瘤细胞凋亡率为28±4.12％，明显高于MMC（2 mg / kg）治疗组（P <0.01）。免疫组织化学染色显示，与Fab（4 mg / kg）组相比，联合组的NPC异种移植物中的VEGF表达被显着抑制（P <0.05）。综上所述，MMC和Fab均可抑制体内NPC异种移植瘤的生长，联合治疗显示出明显的协同抗肿瘤作用，这可能是由于诱导肿瘤细胞凋亡和下调VEGF表达所致。这些结果表明，利用传统化学疗法和抗体靶向疗法的新型联合疗法可能是治疗鼻咽癌的有前途的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号